SCHEMBL354022

SCHEMBL354022

O=C1CCc2cc(Br)ccc2C1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP2A6 P11509 1/20 0.54
METAP1 P53582 1/20 0.47
CYP1A2 P05177 3/20 0.46
CYP3A4 P08684 2/20 0.46
CYP2C9 P11712 2/20 0.46
CYP11B1 P15538 2/20 0.46
CYP11B2 P19099 2/20 0.46
CYP2C19 P33261 2/20 0.46
TDP1 Q9NUW8 1/20 0.46
L3MBTL1 Q9Y468 1/20 0.46
TDP2 O95551 1/20 0.46
ASIC3 Q9UHC3 1/20 0.46
CMA1 P23946 1/20 0.44
AHR P35869 1/20 0.44
PARP10 Q53GL7 2/20 0.42
PARP11 Q9NR21 1/20 0.42
PARP1 P09874 1/20 0.42
SRD5A1 P18405 3/20 0.41
PNMT P11086 1/20 0.41
HSD17B3 P37058 5/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Ethylene SCHEMBL5830934 0.96 CYP2A6 (0.50) CYP2A6METAP1CYP1A2CYP3A4CYP2C9
SCHEMBL415637 0.92 CYP2A6 (0.54) CYP2A6METAP1CYP1A2CYP3A4CYP2C9
Propene SCHEMBL8162420 0.89 CYP2A6 (0.44) CYP2A6METAP1CYP1A2CYP3A4CYP2C9
SCHEMBL6194916 0.88 METAP1 (0.44) CYP2A6METAP1CYP1A2CYP3A4CYP2C9
SCHEMBL10182282 0.87 TDP1 (0.48) CYP2A6METAP1TDP1L3MBTL1TDP2
SCHEMBL2591523 0.85 METAP1 (0.52) CYP2A6METAP1CYP1A2TDP1L3MBTL1
SCHEMBL6195008 0.80 METAP1 (0.44) CYP2A6METAP1TDP1L3MBTL1TDP2
SCHEMBL13594 0.79
Ammonia Solution, Strong SCHEMBL8701960 0.77 PNMT (0.56) METAP1CYP11B1CYP11B2TDP1L3MBTL1
SCHEMBL266510 0.75 CYP2A6 (0.54) CYP2A6CYP1A2CYP3A4CYP2C9CYP11B1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 828 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-109678788-B 1, 2-diaryl indole, derivative and synthetic method thereof 湘潭大学 2021-05-04 CN claimed
CN-107619386-B Aromatic ring [ c ] carbazole derivative and synthesis method thereof 湘潭大学 2020-10-13 CN claimed
WO-2008100621-A2 TETRAHYDRO-PYRAZOLO-PYRIDINE THIOETHER MODULATORS OF CATHEPSIN S SUNESIS PHARMACEUTICALS, INC. (US) 2008-08-21 WO claimed
US-6495023-B1 METHODS USING NEUTRAL RED TO MEDIATE THE INTERCONVERSION OF CHEMICAL AND ELECTRICAL ENERGY. ELECTRICALLY REDUCED NEUTRAL RED HAS BEEN FOUND TO PROMOTE CELL GROWTH AND FORMATION OF REDUCED PRODUCTS BY REVERSIBLY INCREASING THE RATIO OF THE MICHIGAN STATE UNIVERSITY 2002-12-17 US claimed
CN-1314891-A Synthesis of benzo (F) quinolinones LILLY CO ELI (US) 2001-09-26 CN claimed
EP-0969003-A2 Process for the preparation of benzo[f]quinolinone derivatives and intermediates ELI LILLY AND COMPANY (US) 2000-01-05 EP claimed
WO-1999065878-A1 SYNTHESIS OF BENZO[F]QUINOLINONES ELI LILLY AND COMPANY (US) 1999-12-23 WO claimed
EP-0701558-A1 PROCESS OF MAKING SPIROCYCLES AND ANALOGS THEREOF MERCK & CO. INC. (US) 1996-03-20 EP claimed
US-5464762-A Antiarrhythmia MERCK & CO., INC. (US) 1995-11-07 US claimed
WO-1994029317-A1 PROCESS OF MAKING SPIROCYCLES AND ANALOGS THEREOF MERCK & CO., INC. (US) 1994-12-22 WO claimed
CN-122036628-A Iron death inhibitor, preparation method and application thereof 福建医科大学 2026-05-15 CN disclosed
US-12617777-B2 GPR84 antagonists and uses thereof Liminal Biosciences Limited (GB) 2026-05-05 US disclosed
US-12570655-B2 Cysteine covalent modifiers of AKT1 and uses thereof TERREMOTO BIOSCIENCES, INC. (US) 2026-03-10 US disclosed
US-12543495-B2 Composition, organic optoelectronic device and display device SAMSUNG SDI CO., LTD. (KR) 2026-02-03 US disclosed
WO-2025081045-A9 CYSTEINE COVALENT MODIFIERS OF AKT1 AND USES THEREOF TERREMOTO BIOSCIENCES, INC. (US) 2025-12-26 WO disclosed
EP-0343830-A2 Ring-substituted 2-amino-1,2,3,4-tetrahydronaphthalenes ELI LILLY AND COMPANY (US) 1989-11-29 EP disclosed
US-4876340-A Benzazecine derivatives for cognitive and memory functions HOFFMANN-LA ROCHE INC. (US) 1989-10-24 US disclosed
US-4749791-A Benzo[f]quinoline intermediates HOFFMANN-LA ROCHE INC. (US) 1988-06-07 US disclosed
US-4732979-A CEREBRAL INSUFFICIENCY HOFFMANN-LA ROCHE INC. (US) 1988-03-22 US disclosed
EP-0230967-A2 Benzazecine derivatives F. HOFFMANN-LA ROCHE AG (CH) 1987-08-05 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12617777-B2 GPR84 antagonists and uses thereof GPR84, GPR88, GPR3 CYP2A6 2106/4885METAP1 4061/4885CYP1A2 1794/4885
US-12570655-B2 Cysteine covalent modifiers of AKT1 and uses thereof AKT1, AKT2, AKT3 CYP2A6 2153/4885METAP1 3086/4885CYP1A2 4074/4885
US-12543495-B2 Composition, organic optoelectronic device and display device NR2E3, OXER1, ACVRL1 CYP2A6 401/4885METAP1 3582/4885CYP1A2 172/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.